Clinical Trial Update: A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for a study evaluating Telisotuzumab Adizutecan in combination with FOLFOX versus standard of care as first-line treatment for metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Snippet

Sponsor: AbbVie | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, PDAC | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING